Pipeline
We are developing a portfolio of four product candidates, including three product candidates in clinical development and one product candidate in IND-track development. Our pipeline addresses diseases that are not well served by currently available therapies and represent large potential commercial opportunities. We believe that our product candidates offer innovative therapeutic approaches and may provide significant advantages relative to current therapies.
Our most advanced product candidate is pimavanserin, which is being developed, in collaboration with Biovail, for three separate neurological and psychiatric indications, including a Phase III development program for Parkinson's disease psychosis. In addition to pimavanserin, we have AGN XX/YY in Phase II for chronic pain and AC-262271 in Phase I for glaucoma, both in collaboration with Allergan, and AM-831 in IND-track development in collaboration with Meiji Seika Keisha.
Please click on the sub-links to this page to learn more about our product candidates and the targeted disease areas.
back to top